Elena Ter-Ovanesyan

Mersana Therapeutics (United States) — United States

Immunology and Microbiology · Life Sciences

1h-index20citations14works1.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

interferon and immune responses(14), Neuroblastoma Research and Treatments(14), Ubiquitin and proteasome pathways(12), Immune Response and Inflammation(1), Virus-based gene therapy research(1)

Publications14 total

Supplementary Figure S3 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Table S1 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S7 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S4 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S1 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Data from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Table S2 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Table S4 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S2 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S6 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S5 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S8 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Table S3 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
Clinical Cancer Research·2025· 20 citedOpen Access

Frequent Co-authors

Raghida A. Bukhalid(14), Jeremy R. Duvall(14), Kelly L. Lancaster(14), Kalli C. Catcott(14), Naniye Malli Cetinbas(14), Travis Monnell(14), Caitlin Routhier(14), Joshua D. Thomas(14), Keith W. Bentley(14), Scott D. Collins(14), Elizabeth Ditty(14), Timothy K. Eitas(14), Eugene Kelleher(14), Pamela Shaw(14), Jahna Soomer-James(14), Ling Xu(14), Jeffrey Zurita(14), Dorin Toader(14), Marc Damelin(14), Timothy B. Lowinger(14)